Business Wire

NY-ESTÉE-LAUDER

18.6.2020 15:32:11 CEST | Business Wire | Press release

Share
The Estée Lauder Companies Announces That Jane Lauder Will Be Named To The New Role of Executive Vice President, Enterprise Marketing and Chief Data Officer

Today, The Estée Lauder Companies (NYSE:EL) announced that Jane Lauder will be named to the new role of Executive Vice President, Enterprise Marketing and Chief Data Officer, effective July 1, 2020. She will report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC). Jane will be succeeded at Clinique by Michelle Freyre, who will join the brand as Senior Vice President, General Manager, effective July 1, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005543/en/

As ELC’s first ever Enterprise Marketing and Chief Data Officer, Jane will lead our company-wide strategy to build our data-empowered, digitally-directed priorities to accelerate ELC’s growth. By optimizing our vast and valuable data and integrating the company’s analytic capabilities the goal is to drive breakthrough marketing and creative.

“We are focused on delivering the very best, high-quality products that leverage consumer insights from our enhanced data analytics, and I am confident that Jane is the right person to lead this important area of the business,” said Mr. Freda. “As Global Brand President of Clinique and leader of ELC’s enterprise-wide efforts to combine data-driven insights with creativity, she has successfully leveraged data and analytics capabilities to drive strong long-term growth at both the brand and enterprise level. Jane’s unique combination of understanding high-touch consumer experiences, and data analytics and insights, will further strengthen our innovative product offerings and experiences for our consumers globally. I look forward to working even more closely with Jane as she takes on this new role.”

Jane has over two decades of beauty industry experience, including more than 23 years at The Estée Lauder Companies. As Global Brand President of Clinique, she led the transformation of brand strategy, distribution, product innovation and consumer reach, positioning the brand for strong long-term growth. Under Jane’s leadership, Clinique fundamentally shifted nearly one-third of product revenue from low-growth distribution channels to high-growth channels and tripled Clinique’s online business. She also oversaw the development of product innovations including Moisture Surge™ 72-Hour Auto-Replenishing Hydrator and Clinique iD™ and technology innovations with Clinique Clinical Reality™ to strengthen the brand’s skincare position in clinical efficacy and high-touch services and personalization. Clinique’s market share gains in recent months across its core markets are a testament to the rebuilding of the brand.

Jane also leads ELC’s enterprise-wide transformation program focused on combining data and analytics capabilities with creativity to power ELC’s business and digital agenda. In her new role she will continue to drive this competency across the company. As a graduate of Stanford University and member of the Board of Directors of Eventbrite, a California-based global ticketing and event technology platform, Jane’s deep ties to Silicon Valley will be leveraged in her new role.

Jane’s organization will include BI&A, Corporate Marketing and Marketing and Consumer Supported Technology, a forward-looking portfolio management approach to data, marketing and consumer-facing technologies. ELC’s Business Insight & Analytics (BI&A) group will play a central role, and will report directly to Jane with a matrix line into Tracey T. Travis, Executive Vice President and Chief Financial Officer. Jane’s leadership will enable BI&A to continue to accelerate the Company’s ability to unlock value across brands, functions, partners and employees.

Jane will lead the global Corporate Marketing function, including the regional Corporate Marketing organizations, Consumer and Product Marketing Insights, Global Consumer Care and Marketing Planning and A&P effectiveness. She will enable the facilitation and free flow of data among business units to help these teams to mine, analyze and share strategic insights more effectively. She will also enhance the integration of cross-channel data to drive personalized marketing and true omni-channel activation.

Additionally, Jane and her team will ensure that ELC has access to cutting-edge digital innovations through a more formalized approach to strategic digital partnership management, including breakthrough marketing partnerships with leading organizations such as Facebook and Google. Her team will be scouting and developing relationships with emerging influential platforms and players in the marketing, digital innovation and consumer engagement space.

Finally, Jane will be charged with strategically deepening the company’s investments in Talent Management and Capabilities within the Marketing and Consumer Engagement teams, helping to drive talent development, recruitment and breakthrough learning and education programs, making ELC into a career destination of choice for best-in-class brand building, marketing and consumer engagement talent around the world.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye